Nintedanib for Improving Reproductive Outcomes in Adenomyosis

Summary

This study aims to evaluate the effectiveness and safety of nintedanib, an antifibrotic drug, in improving live birth rates for infertile women with adenomyosis who have frozen embryos. Based on promising animal data showing reduced uterine fibrosis, participants will be randomized to receive either standard progesterone therapy plus nintedanib or progesterone therapy alone for three months before undergoing a frozen embryo transfer cycle.

Timeline

Start

2025-09-01

Primary completion

2026-06-30

Completion

2027-06-30

Drugs

Indications